NCT04648696

Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin

Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin in Outpatient Parenteral Antibiotic Therapy: a Prospective, Randomized Trial

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Wake Forest University Health Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the safety and outcomes associated between the two treatment modalities

Detailed description

Assess the risk of vancomycin-associated nephrotoxicity and outcomes associated with continuous infusions (CI) versus II dosing in the outpatient parenteral antibiotic therapy (OPAT) setting

Conditions

• Infection

Interventions

Type	Name	Description
DRUG	Vancomycin CI	The CI group will have their total daily cumulative dose of vancomycin converted to a 24-hour intravenous infusion upon discharge - the CI will begin with the first scheduled OPAT dose of vancomycin
DRUG	Vancomycin II	Study candidates that are randomized to the II group will continue their current intravenous dosing upon discharge

Timeline

• Start date: 2021-03-03
• Primary completion: 2022-10-31
• Completion: 2022-10-31
• First posted: 2020-12-01
• Last updated: 2024-02-14
• Results posted: 2024-02-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study